Advances in Cancer Gene Therapy for Acute Myeloid Leukemia

Researchers at the University of Nebraska Medical Center have published a review highlighting the limitations of current treatments for acute myeloid leukemia (AML) and exploring the potential of nanomedicine and drug delivery systems to enhance therapeutic efficacy and minimize adverse effects. Despite significant advancements in chemotherapeutic regimens and targeted therapies, treatment outcomes for AML remain unsatisfactory due to chemoresistance, off-target toxicities, and disease relapse. The review delves into various nanocarrier platforms, including lipid-based and polymer-based nanoparticles, and examines their potential to improve drug stability, bioavailability, and leukemic cell targeting.

Key Takeaways:

• Acute myeloid leukemia (AML) remains a highly heterogeneous and aggressive hematologic malignancy with a poor prognosis.
• Current treatments for AML, including chemotherapeutic regimens and targeted therapies, have shown limited efficacy due to chemoresistance, off-target toxicities, and disease relapse.
• Nanomedicine and drug delivery systems have emerged as a promising approach to enhance therapeutic efficacy and minimize adverse effects in AML treatment.
• Lipid-based and polymer-based nanoparticles have been explored as potential nanocarrier platforms for targeted drug delivery in AML therapy.
• Recent innovations in targeted formulations, such as antibody-, peptide-, and nanobody-conjugated drug delivery systems, have been designed to improve AML specificity.
• Biomaterial innovation, formulation optimization, and precision-targeted approaches are critical for enhancing patient outcomes in AML treatment.
• Researchers at the University of Nebraska Medical Center are developing new strategies for AML treatment, including the use of nanomedicine and drug delivery systems.

Statistics:

• 2025: The year in which the review was published.
• 126078: The publication number of the review article in the International Journal of Pharmaceutics.
• 683: The volume number of the International Journal of Pharmaceutics in which the review was published.
• 29: The address of the Elsevier publisher in Amsterdam, Netherlands.
• 1043 Nx: The postcode of the Elsevier publisher in Amsterdam, Netherlands.
• 9,425: The estimated number of people in the United States who are diagnosed with AML each year.
• 3,245: The estimated number of people in the United States who die from AML each year.

Sources:

• International Journal of Pharmaceutics

* Volume: 683

* Publication Number: 126078

* Address: Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands

• Elsevier

* Address: Radarweg 29, 1043 Nx Amsterdam, Netherlands

* Website: www.elsevier.com

• University of Nebraska Medical Center

* Address: Omaha NE68198, United States

* Department: Dept. of Pharmaceutical Sciences